soul trial oral semaglutide cardiovascular outcomes (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral GLP-1 receptor agonist Rybelsus

Track your progress in PeptIQ: log your diet, training, weight, and body composition weekly to validate the science against your own results.

But glutathione tablets are given to enhance and support the result of the effects of the injection

The gradual dose-escalation protocol used in clinical trials is specifically designed to minimise their impact

No proprietary blends, just pure, potent components you can trust to support your weight loss journey.

How much weight can I realistically expect to lose while on GLP-1 agonists

After having identical breakfasts at 8:00 am, blood samples were collected from the participants at 9:00 am (T1) followed by oral intake of their CMA or placebo